BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
China's GLP-1 landscape
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
PFA re-energizes afib market
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Saturday, September 14, 2024
See today's BioWorld
See today's BioWorld Asia
Home
» Korea-US biotech Orum plans Kosdaq IPO following $100M+ BMS deal
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Korea-US biotech Orum plans Kosdaq IPO following $100M+ BMS deal
April 30, 2024
By
Marian (YoonJee) Chu
No Comments
Orum Therapeutics Inc., of Boston and Daejeon, South Korea, is planning for an IPO on the Korea Exchange by the end of 2024, having passed a technology evaluation required for listing on the Kosdaq, a company spokesperson confirmed to
BioWorld.
BioWorld
BioWorld Asia
Financings
Cancer
Antibody-drug conjugate
IPO
Asia-Pacific